Physician profile
Pardeep Kumar
NPI 1336251354
$12,983.41
in general payments reported to CMS, 2019-2025
61 companies · $2,599 in 2025
The $2,599 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,258 · 2020: $972 · 2021: $1,002 · 2022: $1,743 · 2023: $2,009 · 2024: $2,401 · 2025: $2,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,969 · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,968.66 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,413.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,216.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,162.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,030.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $902.79 | 2019-2025 | |
| Corcept Therapeutics | $895.31 | 2019-2025 | Korlym |
| Amgen INC. | $755.72 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $670.19 | 2019-2025 | |
| Glaxosmithkline, LLC. | $481.53 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $309.55 | 2019-2023 | |
| Revance Therapeutics, INC. | $283.28 | 2025 | Daxxify |
| Bayer Healthcare Pharmaceuticals INC. | $270.87 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.40 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $233.77 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.48 | 2019-2025 | Trintellix |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $223.11 | 2019-2024 | Verquvo, Gardasil 9, Capvaxive |
| Mylan Specialty L.P. | $181.26 | 2019-2023 | Yupelri |
| Astellas Pharma US INC | $173.82 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.21 | 2019-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $154.77 | 2024-2025 | Voquezna |
| Abbott Laboratories | $142.46 | 2021-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company Ltd. | $131.22 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $118.27 | 2019-2023 | Seglentis |
| Exact Sciences Corporation | $117.24 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $89.52 | 2020-2025 | Eliquis, Camzyos |
| Dexcom, INC. | $86.70 | 2022-2024 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $82.04 | 2023-2025 | Edarbi, Horizant, Horizant |
| Scilex Pharmaceuticals INC. | $78.69 | 2019 | |
| Amarin Pharma, INC. | $62.80 | 2019-2020 | |
| Lundbeck LLC | $62.23 | 2023-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $61.37 | 2023 | Valtoco |
| Axsome Therapeutics, INC. | $59.86 | 2023-2025 | Sunosi, Auvelity |
| Celgene Corporation | $56.95 | 2019 | |
| Eisai INC. | $55.34 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $54.55 | 2023-2024 | Quviviq |
| Currax Pharmaceuticals LLC | $54.23 | 2020-2024 | Contrave, Onzetra Xsail |
| Teva Pharmaceuticals USA, INC. | $54.21 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $51.01 | 2025 | Gvoke Hypopen, Recorlev |
| Mannkind Corporation | $45.42 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $43.59 | 2022-2023 | |
| Seqirus USA INC | $34.13 | 2024-2025 | Flucelvax, Fluad |
| Esperion Therapeutics, INC. | $32.17 | 2025 | Nexletol |
| Antares Pharma, INC. | $31.76 | 2024-2025 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.43 | 2022 | |
| Arbor Pharmaceuticals, INC. | $29.09 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $28.96 | 2021-2023 | Unithroid |
| Radius Health, INC. | $28.26 | 2019 | |
| Duchesnay USA Incorporated | $28.19 | 2019 | |
| Allergan, INC. | $22.94 | 2019 | |
| Axonics, INC. | $21.40 | 2022 | |
| Alnylam Pharmaceuticals INC. | $21.32 | 2024 | Onpattro |
| Ani Pharmaceuticals, INC. | $18.94 | 2025 | Purified Cortrophin Gel |
| Aimmune Therapeutics, INC. | $18.22 | 2024 | |
| Avvisto Therapeutics, LLC | $15.87 | 2025 | Cycloset |
| Halozyme INC | $15.13 | 2023 | |
| Ibsa Pharma INC. | $13.97 | 2021 | |
| Ardelyx, INC. | $13.74 | 2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $12.85 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.40 | 2019 | |
| Almatica Pharma LLC | $12.08 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pardeep Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.